Palbocent 125 mg Capsule (Palbociclib) | (CDK4/6) Inhibitor

Palbocent contains 125 mg of the active pharmaceutical ingredient Palbociclib. It is an orally administered targeted therapy classified as a CDK4/6 inhibitor. Palbocent is utilized exclusively in the management of advanced or metastatic breast cancer that is hormone receptor-positive (HR+) and HER2-negative. By interrupting specific enzymatic pathways that regulate cell division, Palbociclib effectively halts the proliferation of malignant breast tissue cells. It is structurally designed to be used in combination with endocrine (hormone) therapy to overcome acquired clinical resistance and significantly prolong disease control.

“CDK4/6 inhibitors changed the front-line treatment paradigm for HR+/HER2− metastatic breast cancer almost overnight. The single most important thing I tell patients is that neutropenia is not a rare side effect — it is the expected, dose-defining toxicity in the majority of patients. The monitoring schedule is not optional — it is how we catch problems before they become serious.”

— Dr. Salma Mamdouh Elreedy, Clinical Oncologist, Sphinx Cure Oncology Center

What is Palbocent 125 mg?

Palbocent 125 mg is an oral targeted therapy used to treat certain types of advanced or metastatic breast cancer. Its active ingredient is palbociclib, and it belongs to a class of medicines called CDK4/6 inhibitors. Palbocent is manufactured by Incepta Pharmaceuticals as a generic equivalent to the innovator brand Ibrance.

It is always used in combination with another hormone therapy — never on its own. Depending on your situation, your oncologist will prescribe it alongside either an aromatase inhibitor or fulvestrant.

Who is it for?

Palbocent is indicated for adult patients with hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer:

• Postmenopausal women or men, combined with an aromatase inhibitor (such as letrozole), as the first treatment for advanced or metastatic disease.
• Women whose disease has progressed after prior hormone therapy, combined with fulvestrant as second-line treatment.

How does Palbocent work?

In HR+ breast cancer, estrogen signals tell the cancer cell to activate two specific enzymes — CDK4 and CDK6. Think of these enzymes as the “on switch” that allows cancer cells to copy their DNA and divide into new cells.

Palbociclib physically blocks CDK4 and CDK6, trapping cancer cells in the G1 phase of the cell cycle — the phase just before DNA copying begins. This puts the tumour into a state of cellular arrest.

Your companion hormone therapy (letrozole or fulvestrant) reduces the estrogen signal, while palbociclib simultaneously blocks the downstream machinery that signal activates. This dual-attack strategy delays the cancer from developing resistance to treatment, which is why the combination is far more effective than either therapy alone.

How to take Palbocent 125 mg

Your dosing schedule

Palbocent works on a strict 28-day cycle. You take the capsule every day for 21 days, then stop for 7 days to allow your bone marrow to recover. Then you start the next cycle. This pattern continues for as long as your oncologist recommends.

Taking your capsule correctly

• Always take with food — this ensures the drug is properly absorbed. Taking it on an empty stomach significantly reduces how much reaches your bloodstream.
• Swallow capsules whole with a glass of water. Do not chew, crush, or open them.
• Take at the same time every day to maintain stable drug levels.

If you miss or vomit a dose

Do not take an extra dose to make up for a missed or vomited one. Simply take your next dose at the regular time the following day and continue as normal.

Why the 7-day break?

Palbociclib temporarily affects healthy dividing cells in your bone marrow as well as cancer cells. The 7-day rest period allows your white blood cell count — particularly neutrophils, which fight infection — to recover before the next cycle begins. Skipping or shortening this break can lead to dangerously low counts.

Blood tests and monitoring

Because Palbocent commonly lowers white blood cell counts, your oncologist will schedule regular blood tests throughout your treatment. This is not optional — it is how your team keeps you safe.

Dose adjustments

Dose reductions are a normal, planned part of managing Palbocent. They are not a sign that treatment has failed. There are three dose levels: 125 mg → 100 mg → 75 mg — all taken on the same 21/7 schedule.

Never adjust your dose yourself. All changes must be directed by your oncologist based on your blood results and symptoms.

Side effects

Very common (more than 1 in 5 patients)

• Low white blood cells (neutropenia) — expected in most patients; managed with dose adjustments
• Infections — avoid crowded spaces and people who are unwell
• Fatigue
• Nausea — eat small, frequent meals and stay well hydrated
• Mouth sores (stomatitis) — use a soft toothbrush and alcohol-free mouthwash
• Anaemia (low red blood cells)
• Hair thinning (alopecia) — typically mild to moderate, not complete hair loss
• Diarrhoea

Serious side effects — seek immediate medical attention

• Febrile neutropenia: Fever plus low white cell count — contact your team immediately
• Interstitial lung disease / pneumonitis: New or worsening dry cough, shortness of breath, or chest discomfort. Rare but potentially serious — seek emergency care if these develop.
• Severe liver enzyme elevation: Usually caught on routine blood tests; tell your doctor about any yellowing of skin or eyes, dark urine, or severe fatigue.

Medicines and foods to avoid

Palbociclib is processed by a liver enzyme called CYP3A4. Medicines and foods that affect this enzyme can change how much Palbocent is in your bloodstream — either increasing toxicity or reducing effectiveness.

Always tell your oncologist and pharmacist about every medicine, supplement, and herbal product you are taking — including over-the-counter remedies. Review this list at every appointment.

Special situations

Clinical evidence

Palbociclib is backed by two landmark Phase 3 clinical trials — the PALOMA series — which formed the basis for global regulatory approval.

How to store Palbocent 125 mg

• Store at controlled room temperature: 20°C to 25°C (68°F to 77°F). Brief excursions between 15°C and 30°C are permitted.
• Keep in the original blister packaging to protect from moisture and light.
• No refrigeration or cold chain is required.
• Do not use capsules past the expiry date printed on the packaging.
• Dispose of unused or expired capsules according to your local pharmaceutical waste guidelines — not in household rubbish, as Palbocent is classified as a cytotoxic medicine.

Frequently Asked Questions